NCT04143932

Brief Summary

This is a non-interventional, national, multi center, prospective multiple myeloma registry in Turkey

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 30, 2019

Completed
12 months until next milestone

Study Start

First participant enrolled

October 10, 2020

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

July 18, 2023

Status Verified

July 1, 2023

Enrollment Period

4.1 years

First QC Date

October 27, 2019

Last Update Submit

July 15, 2023

Conditions

Multiple MyelomaRelapse Multiple Myeloma

Keywords

multiple myelomaMMRegistryTurkey

Outcome Measures

Primary Outcomes (2)

  • Overall Survival

    Time from the diagnosis to the death

    [Time Frame: 5 Years]

  • Progression Free Survival

    Time from the initiation of treatment to the death from any cause or progression

    [Time Frame: 5 Years]

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients diagnosed as multiple myeloma received maximum 2 lines of therapy will be included to this prospective registry.

You may qualify if:

  • Diagnosed as multiple myeloma
  • Patients signed informed consent form
  • Patients received no more then 2 lines of therapy

You may not qualify if:

  • Patients below 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medipol University

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Omur Gokmen Sevindik, Assoc. Prof.

    Medipol University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Omur Gokmen Sevindik, Assoc. Prof.

CONTACT

+905427870708omurgok17@hotmail.com

Ilker Kurkcu, Pharm

CONTACT

+905326354515ilker.kurkcu@sentez-cro.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2019

First Posted

October 30, 2019

Study Start

October 10, 2020

Primary Completion

December 1, 2024

Study Completion

December 1, 2024

Last Updated

July 18, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations

TU(1)